Search

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

European Affairs

Advocating & collaborating for hematologyEHA serves as the face and voice of hematology and hematology professionals in Europe.

Read more

European Research Initiative on CLL (ERIC)

ERIC is devoted to improving the outcome of patients with Chronic Lymphocytic Leukemia (CLL) and related diseases. The objectives of ERIC are to promote:

Research in all aspects of chronic lymphocytic leukemia and related diseases.

Read more

Priority Points System

The Priority Points System is designed to recognize sponsors’ investment and continuous support for EHA activities, and are allocated for each sponsorship program and/or item.

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more

EHA Kick-off Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more